vascular endothelial growth factor

(redirected from Pazopanib)
Also found in: Dictionary, Medical.

vascular endothelial growth factor

[¦vas·kyə·lər ‚en·dō¦thē·lē·əl ′grōth ‚fak·tər]
(medicine)
A soluble factor that acts through specific cell-surface receptors on endothelial cells to critically regulate vasculogenesis.
McGraw-Hill Dictionary of Scientific & Technical Terms, 6E, Copyright © 2003 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
L'etude a conclu que chez les patients ayant pris un anti-acide pendant au moins 80% de la duree de leur traitement au pazopanib, la duree mediane de survie sans progression du cancer n'a ete que de 2,8 mois, contre 4,6 mois chez ceux qui n'ont pas eu recours au traitement anti-acide.
The differences were not statistically significant for sorafenib and pazopanib. Research payments were not correlated with any statistically significant differences in prescribing for individual drugs.
Drug acquisition costs increased across lines of therapy in the UK (ranging from 5,998 [pounds sterling] in the first line to 20,586 [pounds sterling] in the third line), Spain (2,029 [euro] to 25,446 [euro], resp.), and Germany (4,399 [euro] to 23,540 [euro], resp.), potentially driven by the more common use of branded agents such as pazopanib (Votrient) and trabectedin (Yondelis) in later lines of therapy than in the first line (see Supplementary Tables 13-15).
Katono et al., "Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature," Case Reports in Oncology, vol.
For patients with mRCC, treatment options in the first-line setting include vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs): sunitinib and pazopanib; a monoclonal anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab in combination with interferon-[alpha]; mammalian target of rapamycin (mTOR) inhibitor: temsirolimus; and immunotherapy with high-dose interleukin-2.
The approval of five other antiangiogenic drugs (pazopanib, axitinib, bevacizumab, cabozantinib, and lenvatinib) followed.
A new drug, pazopanib, seems to provide another option with an improved median progression-free survival and median overall survival in some trials.
Lastly, an orally administered antiangiogenic drug, pazopanib was developed by GlaxoSmithKline.
"At best, Fotivda (tivozanib) may have a similar effect as current treatments available on the NHS, sunitinib or pazopanib, but it may not be as good therefore it is not recommended," the draft guidelines said.
Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental endometriosis in Rats.